About Strl Bio
Strl Bio is a Healthcare company based in Hyderabad (India) founded in 2020. Air disinfection systems are provided for hospitals and healthcare institutions. Strl Bio has raised $11.63 thousand across 2 funding rounds from investors including AIC-CCMB. The company has 1 employees. Strl Bio was last valued at $947.77 thousand in June 2022. Its Indian entity Strl Biosystems Private Limited reported revenue of ₹2.96 Cr. Its focus areas include Life Sciences, Hospital Equipment, Hospital Infection Control and Air Sanitization.
Company details
Strl Bio was founded in 2020 and is based in Hyderabad, India. Operations focus on the healthcare sector, where portable air disinfection systems are developed using proprietary BioSterile technology. Nanoparticles and photocatalytic oxidation are employed to produce ions that target and eliminate bacteria, viruses, and fungi in institutional settings. Systems like Strl AIR are designed for use in hospitals to support infection control efforts.
- Headquarters Hyderabad, India
- Employees 1
- SectorsHealthcare
- Website strlbio.com
- Social LinkedIn X Facebook
- Legal Name Strl Biosystems Private Limited
- Date of Incorporation 12 Oct, 2020
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹2.96 Cr
FY 2022 · +8451% YoY
- Net Profit₹1.9 Lakh
FY 2022 · 1% margin
- EBITDA₹3.1 Lakh
FY 2022 · 1% margin
- Total Equity Funding$11.63K (USD)
in 2 rounds
- Investors
- Employee Count1
Associated legal entities of Strl Bio
Strl Bio operates through Strl Biosystems Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2022) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Strl Biosystems Private Limited CIN U33110TG2020PTC144740 | Active | 12 Oct 2020 | Hyderabad, Telangana | ₹3.0 Cr | 2 | View details |
Funding Insights of Strl Bio
Strl Bio has successfully raised a total of $11.63K across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11,630
- Total Rounds 2
- First Round $11,630
(Oct 2021)
- Investors Count 1
All 2 funding rounds of Strl Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
Last known valuation $947,774 (Jun 2022). 1 investors in total: 1 institutional.
Investors in Strl Bio
Strl Bio has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include AIC-CCMB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Sector agnostic startup incubator | 2017 | aic.ccmb.res.in | Hyderabad, India |
Investor details for Strl Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Strl Biosystems Private Limited (Strl Bio)
Strl Biosystems Private Limited is the primary company behind Strl Bio. The board of Strl Biosystems Private Limited currently have 2 directors; the longest-serving is Kalyan Shekhar Kudikala, appointed in 2020.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Kalyan Shekhar Kudikala DIN 06623129 | Director | 12 Oct 2020 | 6 yrs | Strl Biosystems Private Limited |
| Akella Lakshmi Santosha Valli DIN 08914034 | Director | 12 Oct 2020 | 6 yrs | Strl Biosystems Private Limited |
Financials of Strl Bio
Figures of Strl Biosystems Private Limited, the primary company behind Strl Bio, for FY 2022. Revenue was ₹2.96 Cr (+8451% year on year). Net profit was ₹1.9 Lakh (1% margin). EBITDA was ₹3.1 Lakh (1% margin).
- ₹2.96 CrRevenue · FY 2022 · +8451% YoY
- ₹1.9 LakhNet profit · 1% margin
- ₹3.1 LakhEBITDA · 1% margin
- ₹21,470Paid-up capital
Balance sheet, profit and loss, cash flow and ratios of Strl Biosystems Private Limited are on its company page.
Detailed financial statements for Strl Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Strl Bio
3 dated milestones of Strl Bio across 2 years, from founding to its latest funding, stage changes and deals.
- Founded Strl Bio is founded.
- Funding First funding round of $12K.
- Funding Latest funding round, Seed,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Strl Bio
Strl Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Strl Bio is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Strl Bio is a funded company, having raised a total of $11.63K across 2 funding rounds to date. The company's 1st funding round was a Seed of $11.63K, raised on Oct 2021.
Strl Bio has 1 employees.
The primary company behind Strl Bio, Strl Biosystems Private Limited, reported revenue of ₹2.96 Cr for FY 2022, up 8451% year on year.
Strl Bio was founded in 2020 and is based in Hyderabad, India. Operations focus on the healthcare sector, where portable air disinfection systems are developed using proprietary BioSterile technology. Nanoparticles and photocatalytic oxidation are employed to produce ions that target and eliminate bacteria, viruses, and fungi in institutional settings. Systems like Strl AIR are designed for use in hospitals to support infection control efforts.
Strl Bio has 1 investor. Key investors include AIC-CCMB.
The valuation of Strl Bio is $947.77K as of Jun 2022.
Strl Bio operates through Strl Biosystems Private Limited.
The legal entities of Strl Bio currently have 2 directors, including Kalyan Shekhar Kudikala, Akella Lakshmi Santosha Valli.